5-Caffeoylquinic acid decreases diet-induced obesity in rats by modulating PPARα and LXRα transcription.

Abstract

BACKGROUND:

Chlorogenic acids (CGAs) are widely distributed in plant material, including foods and beverages. 5-Caffeoylquinic acid (5-CQA) is the most studied CGA, but the mechanism of its hypolipidaemic effect remains unclear. This study aimed to determine the effect of 5-CQA on lipid metabolism in the liver of Sprague-Dawley rats fed a high-fat diet (HFD).

RESULTS:

5-CQA suppressed HFD-induced increases in body weight and visceral fat-pad weight, serum lipid levels, and serum and hepatic free fatty acids in a dose-dependent manner. Real-time polymerase chain reaction revealed that 5-CQA altered the mRNA expression of the transcription factors peroxisome proliferator-activated receptor α (PPARα) and liver X receptor α (LXRα) and target genes involved in hepatic fatty acid uptake, β-oxidation, fatty acid synthesis, and cholesterol synthesis. Moreover, hepatic tissue sections from HFD-fed rats showed many empty vacuoles, suggesting that liver cells were filled with more fat droplets. However, 5-CQA significantly ameliorated this effect.

CONCLUSION:

5-CQA may improve lipid metabolism disorders by altering the expression of PPARα and LXRα, which are involved in multiple intracellular signalling pathways.

• Authors: Kang Huang, Xiu-ci Liang, Ying-li Zhong, Wan-yan He, Zheng Wang
• Journal: Journal of the science of food and agriculture (J Sci Food Agric) Vol. 95 Issue 9 Pg. 1903-10 (Jul 2015) ISSN: 1097-0010 [Electronic] England
• PMID: 25186103 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2014 Society of Chemical Industry.

Chemical References

• Anti-Obesity Agents
• Antioxidants
• Fatty Acids, Nonesterified
• Hypolipidemic Agents
• Lipids
• Liver X Receptors
• Nr1h3 protein, rat
• Orphan Nuclear Receptors
• PPAR alpha
• Quinic Acid
• Chlorogenic Acid
• 5'-O-caffeoylquinic acid

Topics

• Adiposity
• Animals
• Anti-Obesity Agents (administration & dosage, therapeutic use)
• Antioxidants (administration & dosage, therapeutic use)
• Chlorogenic Acid (administration & dosage, analogs & derivatives, therapeutic use)
• Diet, High-Fat (adverse effects)
• Dietary Supplements
• Fatty Acids, Nonesterified (blood, metabolism)
• Gene Expression Regulation
• Hyperlipidemias (etiology, metabolism, pathology, prevention & control)
• Hypolipidemic Agents (administration & dosage, therapeutic use)
• Lipid Metabolism
• Lipids (blood)
• Liver (metabolism, pathology)
• Liver X Receptors
• Male
• Obesity (etiology, metabolism, pathology, prevention & control)
• Orphan Nuclear Receptors (antagonists & inhibitors, genetics, metabolism)
• PPAR alpha (agonists, genetics, metabolism)
• Quinic Acid (administration & dosage, analogs & derivatives, therapeutic use)
• Random Allocation
• Rats, Sprague-Dawley